Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents

Jae Hoon Kim, Soyoung Won, Chan Bum Choi, Yoon Kyoung Sung, Gwan Gyu Song, Sang Cheol Bae

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: The aim of this study was to evaluate the occurrence of active tuberculosis (TB) in patients who received both an interferon-gamma release assay (the QuantiFERON-TB Gold In-Tube test [QFT-GIT]) and tuberculin skin test (TST) in comparison with those who received QFT-GIT or TST alone for the detection of latent TB infection (LTBI). Methods: In total, 842 patients who received QFT-GIT or TST and used biologic agents between January 2007 and December 2012 were recruited to determine the usefulness of LTBI screening tests. The incidence of active TB was calculated relative to the LTBI screening method as the number of events per 100 000 person-years exposure. Results: TB occurred in two of the patients who complied with an LTBI prophylaxis strategy. The TB incidence in the group that received both QFT-GIT and TST was 151.05 (95% confidence interval [CI] 150.11-151.98)/100 000 person-years, and the incidence was 169.78 (95% CI 168.73-170.84)/100 000 person-years in the group that received only TST. Conclusion: TB occurred even in some patients who received LTBI prophylaxis in compliance with national guidelines. The incidence of TB in patients who received either the QFT-GIT plus TST prophylaxis strategy or the TST prophylaxis strategy alone was higher than the annual incidence of the general population of the Republic of Korea. It is not possible to conclude which of the LTBI prophylaxis strategies is superior.

Original languageEnglish
Pages (from-to)315-322
Number of pages8
JournalInternational Journal of Rheumatic Diseases
Volume18
Issue number3
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Interferon-gamma Release Tests
Latent Tuberculosis
Tuberculin Test
Mycobacterium Infections
Biological Factors
Skin Tests
Mycobacterium tuberculosis
Tuberculosis
Gold
Incidence
Infection
Confidence Intervals
Republic of Korea
Guidelines

Keywords

  • Biologic agent
  • Interferon-gamma release assay
  • Latent tuberculosis infection
  • QuantiFERON-TB Gold In-Tube test
  • Tuberculin skin test

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{f2cf650d42804248912c674e3e130e69,
title = "Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents",
abstract = "Aim: The aim of this study was to evaluate the occurrence of active tuberculosis (TB) in patients who received both an interferon-gamma release assay (the QuantiFERON-TB Gold In-Tube test [QFT-GIT]) and tuberculin skin test (TST) in comparison with those who received QFT-GIT or TST alone for the detection of latent TB infection (LTBI). Methods: In total, 842 patients who received QFT-GIT or TST and used biologic agents between January 2007 and December 2012 were recruited to determine the usefulness of LTBI screening tests. The incidence of active TB was calculated relative to the LTBI screening method as the number of events per 100 000 person-years exposure. Results: TB occurred in two of the patients who complied with an LTBI prophylaxis strategy. The TB incidence in the group that received both QFT-GIT and TST was 151.05 (95{\%} confidence interval [CI] 150.11-151.98)/100 000 person-years, and the incidence was 169.78 (95{\%} CI 168.73-170.84)/100 000 person-years in the group that received only TST. Conclusion: TB occurred even in some patients who received LTBI prophylaxis in compliance with national guidelines. The incidence of TB in patients who received either the QFT-GIT plus TST prophylaxis strategy or the TST prophylaxis strategy alone was higher than the annual incidence of the general population of the Republic of Korea. It is not possible to conclude which of the LTBI prophylaxis strategies is superior.",
keywords = "Biologic agent, Interferon-gamma release assay, Latent tuberculosis infection, QuantiFERON-TB Gold In-Tube test, Tuberculin skin test",
author = "Kim, {Jae Hoon} and Soyoung Won and Choi, {Chan Bum} and Sung, {Yoon Kyoung} and Song, {Gwan Gyu} and Bae, {Sang Cheol}",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/1756-185X.12515",
language = "English",
volume = "18",
pages = "315--322",
journal = "International Journal of Rheumatic Diseases",
issn = "1756-1841",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents

AU - Kim, Jae Hoon

AU - Won, Soyoung

AU - Choi, Chan Bum

AU - Sung, Yoon Kyoung

AU - Song, Gwan Gyu

AU - Bae, Sang Cheol

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Aim: The aim of this study was to evaluate the occurrence of active tuberculosis (TB) in patients who received both an interferon-gamma release assay (the QuantiFERON-TB Gold In-Tube test [QFT-GIT]) and tuberculin skin test (TST) in comparison with those who received QFT-GIT or TST alone for the detection of latent TB infection (LTBI). Methods: In total, 842 patients who received QFT-GIT or TST and used biologic agents between January 2007 and December 2012 were recruited to determine the usefulness of LTBI screening tests. The incidence of active TB was calculated relative to the LTBI screening method as the number of events per 100 000 person-years exposure. Results: TB occurred in two of the patients who complied with an LTBI prophylaxis strategy. The TB incidence in the group that received both QFT-GIT and TST was 151.05 (95% confidence interval [CI] 150.11-151.98)/100 000 person-years, and the incidence was 169.78 (95% CI 168.73-170.84)/100 000 person-years in the group that received only TST. Conclusion: TB occurred even in some patients who received LTBI prophylaxis in compliance with national guidelines. The incidence of TB in patients who received either the QFT-GIT plus TST prophylaxis strategy or the TST prophylaxis strategy alone was higher than the annual incidence of the general population of the Republic of Korea. It is not possible to conclude which of the LTBI prophylaxis strategies is superior.

AB - Aim: The aim of this study was to evaluate the occurrence of active tuberculosis (TB) in patients who received both an interferon-gamma release assay (the QuantiFERON-TB Gold In-Tube test [QFT-GIT]) and tuberculin skin test (TST) in comparison with those who received QFT-GIT or TST alone for the detection of latent TB infection (LTBI). Methods: In total, 842 patients who received QFT-GIT or TST and used biologic agents between January 2007 and December 2012 were recruited to determine the usefulness of LTBI screening tests. The incidence of active TB was calculated relative to the LTBI screening method as the number of events per 100 000 person-years exposure. Results: TB occurred in two of the patients who complied with an LTBI prophylaxis strategy. The TB incidence in the group that received both QFT-GIT and TST was 151.05 (95% confidence interval [CI] 150.11-151.98)/100 000 person-years, and the incidence was 169.78 (95% CI 168.73-170.84)/100 000 person-years in the group that received only TST. Conclusion: TB occurred even in some patients who received LTBI prophylaxis in compliance with national guidelines. The incidence of TB in patients who received either the QFT-GIT plus TST prophylaxis strategy or the TST prophylaxis strategy alone was higher than the annual incidence of the general population of the Republic of Korea. It is not possible to conclude which of the LTBI prophylaxis strategies is superior.

KW - Biologic agent

KW - Interferon-gamma release assay

KW - Latent tuberculosis infection

KW - QuantiFERON-TB Gold In-Tube test

KW - Tuberculin skin test

UR - http://www.scopus.com/inward/record.url?scp=84928524194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928524194&partnerID=8YFLogxK

U2 - 10.1111/1756-185X.12515

DO - 10.1111/1756-185X.12515

M3 - Article

VL - 18

SP - 315

EP - 322

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

SN - 1756-1841

IS - 3

ER -